Bio-Techne FY2027 Q1: sales up 4.6%, EPS down to $0.18
Bio-Techne's FY2027 Q1 is Neutral: revenue rose 4.6% to $299.7 million and gross margin held at 65.6%, but SG&A growth pushed operating income and EPS lower. Read the quarter as a margin-mix test rather than a demand break: cash flow was strong, the balance sheet has $350.0 million of cash, and the pending Merck merger plus the Wilson Wolf obligation matter more than any guidance, which the input does not provide.
1 · Expected vs. Actual
Free preview belowDiluted EPS fell to $0.18 from $0.24, and net income dropped to $28.3 million from $38.2 million. Operating income was $36.6 million, down from $47.7 million, because SG&A rose to $133.7 million from $116.2 million. R&D increased to $26.3 million from $24.2 million, so the profit squeeze was mostly spending, not gross margin.
Revenue was $299.7 million, up 4.6% from $286.6 million a year earlier. Product and services brought in $285.2 million, while royalties were $14.5 million. Gross margin was 65.6%, essentially flat with the prior-year quarter.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-11-06
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.